Publications by authors named "A Pinto-Correia"
Article Synopsis
- Atopic dermatitis (AD) is a chronic skin condition with few treatment options for teens, and lebrikizumab, an antibody targeting IL-13, shows potential benefits in treating it, based on previous studies.
- The Phase 3 ADore study involved 206 adolescents with moderate-to-severe AD, who received lebrikizumab and were monitored for safety and effectiveness over 52 weeks.
- Out of 172 participants who completed the study, many experienced improvements, such as 65% achieving significant reductions in disease severity, while serious side effects were infrequent, indicating the treatment's promise for managing AD in adolescents.
Background And Aims: There is an unmet need for alternative treatments for patients with primary biliary cholangitis (PBC) who do not respond to treatment with ursodeoxycholic acid (UDCA). A proof-of-concept study of baricitinib, an orally administered Janus kinase 1 and 2 inhibitor, was initiated to evaluate its use in PBC patients.
Approach And Results: Patients with PBC showing inadequate response or intolerance to UDCA were eligible.
Objectives: This study investigated the effects of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day.
Methods: Patients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥15 months and maintained CDAI low disease activity (LDA) or remission (REM) were blindly randomised to continue 4 mg or taper to 2 mg.
Aim: To evaluate the efficacy and safety of endoscopic sphincterotomy (EST) + endoscopic papillary large balloon dilation (EPLBD) vs isolated EST.
Methods: We conducted a retrospective single center study over two years, from February 2010 to January 2012. Patients with large (≥ 10 mm), single or multiple bile duct stones (BDS), submitted to endoscopic retrograde cholangio-pancreatography (ERCP) were included.
Introduction: The Epstein-Barr virus (EBV) persists for long periods in latent state inside B-lymphocytes after primary infections, and reactivation usually occurs associated to immunosuppression conditions of the host. Recently, the detection of EBV DNA in circulation has been suggested as a predictor marker for the development of EBV related malignancies.
Aim Of The Study: The aim of our study was to characterize the frequency of circulating EBV in healthy individuals (n=508) from the North region of Portugal, using peripheral blood samples.